Evidence map›Paper›PMID 25100849›Full record

ArticleJournal of virology2014

trans-Protease activity and structural insights into the active form of the alphavirus capsid protease.

Megha Aggarwal, Sonali Dhindwal, Pravindra Kumar, Richard J Kuhn, Shailly Tomar

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Functional Study of the Retrotransposon-Derived Human PEG10 Protease.International journal of molecular sciences · 2020
    Article
  5. Review
  6. Article
  7. A novel system for visualizing alphavirus assembly.Journal of virological methods · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Megha AggarwalDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India.
Sonali DhindwalDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India.
Pravindra KumarDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India.
Richard J KuhnDepartment of Biological Sciences and Bindley Bioscience Center, Purdue University, West Lafayette, Indiana, USA.
Shailly TomarDepartment of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India shailfbt@iitr.ac.in.
Indian Institute of Technology Roorkee · INPurdue University West Lafayette · US

Funding

MOLECULAR BASIS OF ALPHAVIRUS ASSEMBLYR01GM056279 · NIGMS · PURDUE UNIVERSITY WEST LAFAYETTE · PI KUHN, RICHARD J. · 1997 to 2014
$3.7M
NIGMS NIH HHS GM56279NIGMS NIH HHS R01 GM056279
6 · The paper itself

Abstract

The alphavirus capsid protein (CP) is a serine protease that possesses cis-proteolytic activity essential for its release from the nascent structural polyprotein. The released CP further participates in viral genome encapsidation and nucleocapsid core formation, followed by its attachment to glycoproteins and virus budding. Thus, protease activity of the alphavirus capsid is a potential antialphaviral target to arrest capsid release, maturation, and structural polyprotein processing. However, the discovery of capsid protease inhibitors has been hampered due to the lack of a suitable screening assay and of the crystal structure in its active form. Here, we report the development of a trans-proteolytic activity assay for Aura virus capsid protease (AVCP) based on fluorescence resonance energy transfer (FRET) for screening protease inhibitors. Kinetic parameters using fluorogenic peptide substrates were estimated, and the K(m) value was found to be 2.63 ± 0.62 μM while the k(cat)/K(m) value was 4.97 × 10(4) M(-1) min(-1). Also, the crystal structure of the trans-active form of AVCP has been determined to 1.81-Å resolution. Structural comparisons of the active form with the crystal structures of available substrate-bound mutant and inactive blocked forms of the capsid protease identify conformational changes in the active site, the oxyanion hole, and the substrate specificity pocket residues, which could be critical for rational drug design. IMPORTANCE The alphavirus capsid protease is an attractive antiviral therapeutic target. In this study, we have described the formerly unappreciated trans-proteolytic activity of the enzyme and for the first time have developed a FRET-based protease assay for screening capsid protease inhibitors. Our structural studies unveil the structural features of the trans-active protease, which has been previously proposed to exist in the natively unfolded form (M. Morillas, H. Eberl, F. H. Allain, R. Glockshuber, and E. Kuennemann, J. Mol. Biol. 376:721-735, 2008, doi:http://dx.doi.org/10.1016/j.jmb.2007.11.055). The different enzymatic forms have been structurally compared to reveal conformational variations in the active and substrate binding sites. The flexible active-site residue Ser218, the disordered C-terminal residues after His261, and the presence of a water molecule in the oxyanion hole of AVCPΔ2 (AVCP with a deletion of the last two residues at the C terminus) reveal the effect of the C-terminal Trp267 deletion on enzyme structure. New structural data reported in this study along with the fluorogenic assay will be useful in substrate specificity characterization, high-throughput protease inhibitor screening, and structure-based development of antiviral drugs.

Indexed as

AlphavirusCapsid ProteinsCrystallography, X-RayDrug Evaluation, PreclinicalFluorescence Resonance Energy TransferKineticsModels, MolecularPeptide HydrolasesProtease InhibitorsProtein ConformationCapsid ProteinsPeptide HydrolasesProtease Inhibitors

Identifiers

PMID25100849
PMCPMC4248945
OpenAlexW2100643644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.